KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Current Investments (2020 - 2025)

AbCellera Biologics' Cash & Current Investments history spans 6 years, with the latest figure at $108.2 million for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 28.67% year-over-year to $108.2 million, compared with a TTM value of $108.2 million through Sep 2025, down 28.67%, and an annual FY2024 reading of $181.3 million, up 14.53% over the prior year.
  • Cash & Current Investments for Q3 2025 was $108.2 million at AbCellera Biologics, down from $117.4 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $815.6 million in Q2 2022, with the low at $108.2 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $423.8 million, with a median of $372.0 million recorded in 2022.
  • Year-over-year, Cash & Current Investments soared 39.33% in 2023 and then tumbled 83.11% in 2025.
  • Tracing ABCL's Cash & Current Investments over 5 years: stood at $501.1 million in 2021, then plummeted by 43.07% to $285.3 million in 2022, then crashed by 44.51% to $158.3 million in 2023, then grew by 14.53% to $181.3 million in 2024, then crashed by 40.35% to $108.2 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Cash & Current Investments are $108.2 million (Q3 2025), $117.4 million (Q2 2025), and $184.3 million (Q1 2025).